Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio to Distribute BellBrook's Assay for Epigenetics Research

NEW YORK (GenomeWeb News) – Cisbio Bioassays today announced a deal to distribute BellBrook Labs' Transcreener Epigen Methyltransferase assay.

Under the terms of the agreement, the second distribution deal between the companies, Cisbio will offer the assay for epigenetics-based drug discovery studies conducted by pharmaceutical and biotechnology researchers in the US, Europe, and Asia.

Transcreener Epigen Methyltransferase is a universal detection method based on Transcreener AMP/GMP assay technology developed by BellBrook that involves coupling enzymes for detection of methyltransferase reaction products. The products are crucial targets in epigenetics research, the partners said.

Financial and other terms of the deal were not disclosed.

In 2008 Cisbio and BellBrook teamed up to launch HTRF Transcreener ADP, an assay for the high-throughput screening and profiling of kinases.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.